| Identification | Back Directory | [Name]
Vatalanib succinate | [CAS]
212142-18-2 | [Synonyms]
VATALANIB SUCCINATE
N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine succinate
N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine succinate
N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine butanedioate
butanedioicacid,N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine | [Molecular Formula]
C24H21ClN4O4 | [MDL Number]
MFCD08435979 | [MOL File]
212142-18-2.mol | [Molecular Weight]
464.9 |
| Hazard Information | Back Directory | [Uses]
Vatalanib Succinate is a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases. | [Definition]
ChEBI: A succinate salt obtained by combining vatalanib with one molar equivalent of succinic acid. It is a multi-targeted tyrosine kinase inhibitor for all isoforms of VEGFR, PDGFR and c-Kit. | [in vivo]
After oral dosing (50 mg/kg) to mice, plasma concentrations of Vatalanib (PTK787) remain above 1 μM for more than 8 h. Vatalanib (PTK787) induces dose-dependent inhibition of VEGF and PDGF-induced angiogenesis in a growth factor implant model, as well as a tumor cell-driven angiogenesis model after once-daily oral dosing (25-100 mg/kg)[1]. | [IC 50]
KDR: 37 nM (IC50); Flt-1: 77 nM (IC50); Flt-4: 730 nM (IC50) | [storage]
Store at -20°C |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|